SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is a focal point of discussion due to a congressional probe into its $500 million investment with an Abu Dhabi entity and its ongoing application for a National Trust Bank Charter. This has sparked intense debate, with some community members forecasting substantial growth from its forthcoming real-world asset platform and app, while others strongly denounce it as a fraudulent scheme.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after its swift decision to cease offering a compounded weight-loss pill following regulatory scrutiny and legal threats from major pharmaceutical companies. The community is divided, with some viewing it as a strategic de-risking move for its core telehealth business, while others criticize it as a major management blunder that damages trust and growth, amidst mixed reactions to its Super Bowl advertisement.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting volume is anticipated, with community discussion intensely focused on how burgeoning prediction markets, operating under different regulatory frameworks, will impact its future profitability and market share amidst its own expansion into the evolving sector ahead of its impending earnings report.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to widespread discussions surrounding a potential future merger involving SpaceX and xAI, alongside recent announcements about high-volume Semi production and significant investments in AI, robotics, and autonomous driving. This is fueling bullish outlooks for its long-term vision, though the community also expresses concerns about near-term profitability and ongoing controversies related to its CEO.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid a federal probe into alleged workplace discrimination and high anticipation for a Supreme Court ruling on tariffs that could impact its margins. While some in the community are betting on a strategic turnaround driven by new product innovation and North American growth, others remain skeptical, citing continued weakness in key markets.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following its recent acquisition and new financing designed to strengthen its HAE portfolio, yet community discussion remains largely negative, citing persistent stock undervaluation, increasing short interest, and perceived manipulation, further fueled by public comments from well-known financial personalities.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics (CAPR) is trending as the FDA requested the full HOPE-3 Clinical Study Report for its Duchenne muscular dystrophy therapy, Deramiocel, marking a crucial step in the BLA review without requiring new clinical trials. The community views this as a de-risked path to approval, highlighting the therapy's unique cardiac benefits and anticipating further catalysts from its StealthX platform amidst growing institutional interest.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the Square and Cash App segments. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. It also includes Cash App Card, which is linked to customer stored balances that customers can use to pay for purchases or withdraw funds from an ATM. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is gaining significant attention due to its critical role in cutting-edge defense contracts for AR systems like Anduril's EagleEye and surging demand for its space and AI infrastructure optics, with community discussion highlighting its exceptionally tight float and strong insider ownership as key bullish factors.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following a recently announced $250 million financing amendment that extends its capital runway through 2028, fueling community speculation about a potential short squeeze and comparisons to its history of massive parabolic price movements. While many anticipate significant upward momentum, a notable counter-narrative raises concerns about potential dilution from the equity line of credit and the company's underlying profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>China granted Priority Review for an at-home Alzheimer’s treatment developed by Biogen and Eisai.</li><li>If approved, the subcutaneous version would allow once-weekly at-home&nbsp;dosing instead of biweekly hospital IV infusions.</li><li>Analysts also raised price targets following Biogen’s Q4 earnings beat.</li></ul>Shares of Biogen (BIIB) drew heightened retail chatter late Sunday after the company and partner Eisai said China’s drug regulator granted Priority Review to a subcutaneous formulation of Leqembi for the treatment of early Alzheimer’s disease.<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> jumped 9% on Friday to close at $201.18, marking its highest level in more than 16 months and its best session in over four months.<h2 class="st-heading-2">Leqembi At-Home Dosing</h2>If approved, the subcutaneous formulation would enable once-weekly at-home dosing, rather than the intravenous dosing administered every two weeks at the hospital under the current regimen. The companies noted that each autoinjector delivers a 250 mg dose in about 15 seconds, requiring two injections per weekly dose.&nbsp;Leqembi was launched in China in 2024 and was added to the country’s Commercial Insurance Innovative Drug List effective January 2026, under policies supporting access to innovative medicines. Eisai leads global development and regulatory submissions for Leqembi, and it and Biogen co-commercialize the product.<h2 class="st-heading-2">Analysts Raise Targets After Q4 Results</h2>Biogen also saw a wave of target hikes following its fourth-quarter (Q4) earnings report.Wells Fargo raised its price target to $200 from $190, implying a 0.6% downside from its last close and kept an 'Equal Weight' rating, saying it expects the company’s 2026 launch execution to remain steady and that near-term late-stage catalysts could improve the outlook toward the end of the decade.&nbsp;Bank of America lifted its price target to $207 from $189, implying a 3% upside from current levels, and maintained a 'Neutral' rating, attributing the post-earnings share rally to what it called “clear positives” from the earnings call, including “not as bad as feared erosion” of the multiple sclerosis franchise.&nbsp;Morgan Stanley raised its price target to $190 from $156, implying a 6% downside from current levels, and kept an 'Equal Weight' rating, saying the company’s “building” pipeline is now the focus following the Q4 report.&nbsp;Citi increased its price target to $215 from $185, implying a 7% upside from last close, and reiterated a 'Neutral' rating, saying it views the Q4 report as solid and remains optimistic about Biogen’s ability to launch new products and develop its pipeline.&nbsp;BMO Capital raised its price target to $196 from $165, implying a 3% downside from its last close, and kept a 'Market Perform' rating. The firm said revenue erosion from the multiple sclerosis business is expected to continue in 2026, but added it is growing more confident in the long-term opportunity for high-dose Spinraza and upcoming Litifilimab readouts in systemic lupus erythematosus.&nbsp;<h2 class="st-heading-2">BIIB Q4 Earnings</h2>Biogen reported Q4 adjusted earnings per share (EPS) of $1.99, above consensus expectations of $1.63, on revenue of $2.3 billion, compared with a $2.2 billion consensus.&nbsp;For full-year 2026, the company guided to adjusted EPS of $15.25–$16.25, above the consensus estimate of $14.95, and forecast revenue to decline mid-single digits versus 2025. Biogen also said its adjusted effective tax rate for 2026 is expected to be 17%–18%, with gross margin and combined non-GAAP research and development (R&amp;D) and administrative expenses roughly consistent year over year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for BIIB was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/biib_ss_png_61b28cbdcd.webp" alt="biib ss.png" width="971" height="142"><figcaption>BIIB sentiment and message volume as of February 8 | Source: Stocktwits</figcaption></figure>One user said the stock stands out as a “high-quality large-cap biotech with real optionality,” citing a strong balance sheet, durable cash flows from its core neurology franchise, and multiple shots on goal across Alzheimer’s, depression, and rare neuro diseases.<stembedurl>https://stocktwits.com/MoleculeHunterX/message/644276931</stembedurl>Another user said, “feel like we should be over $200 already 210 or so. Hopefully this keeps momentum and goes to $220”<stembedurl>https://stocktwits.com/gratefultobe/message/644236362</stembedurl>BIIB stock has risen 41% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi

Analyst price targets for BIIB are in the range of $190 to $215, implying a downside of about 6% to an upside of nearly 7% from the last close.

Equity

Twin Capital Management Inc. Sells 5,246 Shares of Biogen Inc. $BIIB

Twin Capital Management Inc. decreased its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 43.6% in the third quarter, according to the company in its most recent 13F filing with the...

Penserra Capital Management LLC Has $706,000 Holdings in Biogen Inc. $BIIB

Penserra Capital Management LLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 41,941.7% during the third quarter, according to its most recent 13F filing with the SEC. The...

Stifel Nicolaus Increases Biogen (NASDAQ:BIIB) Price Target to $214.00

Stifel Nicolaus lifted their price objective on shares of Biogen from $202.00 to $214.00 and gave the company a "buy" rating in a research note on Friday...

Why Biogen Stock Surged Almost 9% Higher on Friday

Key PointsThe biotech published its last set of financials for 2025...

Biogen (NASDAQ:BIIB) Posts Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Biogen (NASDAQ:BIIB - Get Free Report) issued its earnings results on Friday. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.72 by...

BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View

Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.

Pre-Markets Open in Green to Close the Week

Pre-Markets Open in Green to Close the Week.

Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump

Biogen beat fourth-quarter earnings and revenue estimates as growth from Leqembi, Skyclarys, and Zurzuvae offset declining multiple sclerosis sales, while the company forecast higher 2026...

Pre-Markets Rebounding Ahead of Super Bowl Sunday

We're seeing is a slight uptick at this hour for companies like Draft Kings (DKNG) and FanDuel parent Flutter (FLUT).

$BIIB Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.33 down -118.03% YoY
• Reported revenue of $2.28B down -7.14% YoY
• Biogen expects full year 2026 Non-GAAP diluted EPS to be between $15.25 and $16.25. Total revenue is anticipated to decline by a mid-single digit percentage compared to full year 2025.

Stocktwits

Biogen Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.33 down -118.03% YoY
• Reported revenue of $2.28B down -7.14% YoY
• Biogen expects full year 2026 Non-GAAP diluted EPS to be between $15.25 and $16.25. Total revenue is anticipated to decline by a mid-single digit percentage compared to full year 2025.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

What will be the S&P 500’s next 5% move?

BIIB
Biogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIIB News

BIIBBiogen Inc